There is a growing awareness in primary care of the importance of identifying patients with chronic kidney disease (CKD) so that they can receive appropriate clinical care; one method that has been widely embraced is the use of automated reporting of estimated glomerular filtration rate (eGFR) by clinical laboratories. We undertook a qualitative study to examine how clinicians use eGFR in clinical decision making, patient communication issues, barriers to use of eGFR, and suggestions to improve the clinical usefulness of eGFR reports.
Our study used qualitative methods with structured interviews among primary care clinicians including both physicians and allied health providers, recruited from Kaiser Permanente Northwest, a non-profit health maintenance organization.
We found that clinicians generally held favorable views toward eGFR reporting but did not use eGFR to replace serum creatinine in their clinical decision-making. Clinicians used eGFR as a tool to help identify CKD, educate patients about their kidney function and make treatment decisions. Barriers noted by several clinicians included a desire for greater education regarding care for patients with CKD and tools to facilitate discussion of eGFR findings with patients.
The manner in which clinicians use eGFRs appears to be more complex than previously understood, and our study illustrates some of the efforts that might be usefully undertaken (e.g. specific clinician education) when encouraging further promulgation of eGFR reporting and usage.
Pre-dialysis chronic kidney disease (CKD) is a common condition with an estimated prevalence of more than 13% of the US population [
Using eGFR has its own disadvantages, such as underestimating renal function in healthy individuals, leading to increased false positive diagnoses [
Many factors likely influence how health care providers use laboratory tests. For example, a provider’s knowledge of the patient’s clinical situation, their reimbursement, and understanding of the sensitivity and specificity probably all influence how often a test is ordered and how it is interpreted and used clinically [
The study was conducted in 2010 (April through June) at a nonprofit group-model health-maintenance organization (HMO), Kaiser Permanente Northwest (KPNW), in Washington and Oregon. The site has 15 medical centers and approximately 485,000 members. Electronic databases provided administrative and clinical data and a full electronic medical record (EMR) has been in place since 1996. The study was approved by the institutional review board at KPNW and clinician participants provided written informed consent.
The EMR and related systems used at KPNW contain several tools that clinicians can use to automate functions. Several of these automated tools were referred to by our participants so we give a brief description of them here. The Panel Support Tool (PST) is a ‘dashboard’ indicator of potential care gaps that are reported at the patient level. For example, it reports on the current status of testing and follow-up for patients with diabetes, cardiovascular disease, asthma and CKD, among other co-morbid conditions, and recommends treatment and testing strategies to close the care gaps. The EMR also allows the creation of ‘dot phrases’ that can be used, for example, to automatically populate text in clinical notes and in patient letters.
Our study was designed to take advantage of a systematic change at KPNW where all laboratory locations began automatically reporting eGFR routinely with serum creatinine in its laboratory results to clinicians. This reporting began on February 1, 2004. Prior to this, only the serum creatinine value was reported to clinicians on laboratory reports. The laboratory used the 4 variable version of the Modification in Diet and Renal Disease (MDRD) Study [
Qualitative methods are effective strategies for documenting and analyzing unique, complex social phenomena, such as clinician experiences with a “newly” reported lab value [
We identified a list of 139 Family Practice (FP) or Internal Medicine (IM) based primary care providers (PCPs) who had been employed with KPNW from at least January 2002 to the present. This time frame was chosen so that clinicians could speak about their experiences of eGFR both before and after automatic reporting began in 2004. We included clinicians who were either physicians (MD) or allied health practitioners (NP or PA). We aimed to interview a minimum of 16 PCPs, a number we determined as sufficient for reaching redundancy of information and themes based on prior experience with qualitative methods and interviewing clinicians. Of these 16 clinicians, our goal was to interview 8 allied health practitioners (distributed equally between IM and FP), and 8 MDs (distributed equally between IM and FP). We also attempted to balance the participants geographically across the 13 clinics. Clinicians were recruited by email, sent by the Chief of Nephrology (co-author MLT), inviting them to participate in a 30 minute structured interview. Lunch was provided to the participants. We completed 19 in-depth individual interviews with PCPs. Of these, 13 were MDs (8 IM, 5 FP) and 6 were allied health practitioners (2 IM, 4 FP). We sent 89 individual recruitment emails to reach this total, with 64 participants providing no response to the email and 6 participants indicating scheduling conflicts or lack of time as their reason for not participating.
The research team developed a structured guide (based upon prior experience [
We interviewed 19 clinicians, 10 in the department of IM, 9 in the department of FP (Table
Participant Demographics
| | |||
|---|---|---|---|
| 8 IM; 5 FP | 2 IM; 4 FP | 10 IM; 9 FP | |
| Range 2–30; | Range 11–22; | | |
| | Ave: 16.3 | Ave: 18.5 | |
| 4 FTE; 9 PTE | 4 FTE; 2 PTE | | |
| Range 700–2044; | Range 1000–1405; | | |
| | Ave: 1251 | Ave: 1176*** | |
| 9 | 2 |
* 2 nurse practitioners; 4 physician assistants;
** Includes all clinicians with date of service from at least January 2002 to present (gaps in employment permissible).
*** 2 Allied physicians without their own patient panel to manage.
**** Other roles include such things as: provider/resident education and communication; urgent care; clinical director; team lead; health plan board member; document and coding; recruitment and retention; and home health/hospice work.
We asked clinicians about their use of eGFR prior to, and after, automated eGFR reporting was instituted. About half of the physicians said they had, at least sometimes, calculated eGFR before the implementation of automated reporting, while none of the allied health professionals did so. In fact, all the clinicians said they had primarily used serum creatinine as their gauge of kidney health before automated reporting (Table
Comparison of Use of eGFR Value Prior to, and After, Automatic Reporting (n = 19)
| | | | ||
| · sometimes to occasionally | 6 | 0 | 6 | |
| · rarely to never | 7 | 6 | 13 | |
| | | | | |
| · yes | 13 | 6 | 19 | |
| | | |||
| | | | ||
| · yes | 8 | 4 | 12 | |
| · no / not much | 5 | 2 | 7 | |
| | | | | |
| · uses both | 11 | 4 | 15 | |
| · uses eGFR more often | 2 | 1 | 3 | |
| · uses creatinine more often | 0 | 1 | 1 | |
When asked about whether their overall approach to CKD management had changed since automated eGFR reporting, more than half of the clinicians said that it had. However, a minority said their overall approach had not changed, and by clinician type, there seemed to be little difference in whether management of CKD had changed. We found that the majority of clinicians reported currently using both eGFR and serum creatinine in clinical decision-making. Only one clinician reported currently using serum creatinine more often than eGFR.
Clinicians’ perceived benefits of automated eGFR included time savings, increased disease awareness and improved patient care. Clinicians mentioned that having the eGFR calculated saved them valuable clinic time because it streamlined their work and removed the need for calculating it themselves. For example an internal medicine clinician commented (Table
[Previously] I would very frequently have to look up their kidney function and actually calculate the GFR…So, definitely in an older population you encounter that often with certain medications. When automatic reporting came on, it was really helpful. I’ve never calculated it since then, and I said to myself, ‘Oh, that’s so going to save me time!’.
Overall Impact of eGFR Automatic Reporting: Benefits and Challenges (n = 19)
| · automatic calculation and reporting makes approach and work to CKD management more streamlined | |
| · easier to have eGFR calculated for provider - saves valuable clinic time to not calculate equation on own when they need it | |
| · providers wish they had the automatic eGFR value prior | |
| · providers feel the missed opportunity to help some patients by not having the automatic value previously | |
| · believe it to be a good clinical tool | |
| · helpful to have a more precise picture of renal health and CKD staging than just creatinine could provide | |
| · created more awareness of and attention to tracking CKD in general | |
| · now know about and can manage all the patients provider did not know about before automatic reporting began that have a “normal or slightly abnormal” creatinine and an abnormal eGFR | |
| · identified a pool of patients on providers’ panel with CKD status much worse than the creatinine value alone was indicating – would not have “known” about these patients or referred on to Nephrology without automatic reporting | |
| · overall provide better patient care by having the automatic eGFR value | |
| · improves the ability of providers to assess and act on a patient’s renal health and functioning earlier or to determine appropriate referral to Nephrology at earlier time points | |
| · greatly helps in medication management efforts, including determining both the appropriate type and dosage of medication | |
| · helps provider manage the Medicare refresh diagnosis process related to CKD status | |
| · initially caused some otherwise healthy patients concern and upset regarding “suddenly” having a CKD diagnosis | |
| · initially caused some otherwise healthy patients undue fear and stress regarding their kidney health and future possibility of dialysis | |
| · initial reporting created a “new”, “unknown”, and “larger” pool of patients in Stage 3 that now needed outreach and follow-up | |
| · initially created a “thinking” burden when trying to determine the correct e GFR value on lab report – (both African American and Caucasian values reported) | |
| · generated more follow up and tracking work for providers – another condition to now follow and manage | |
| · extra time and workload for provider to create their own systems and processes for tracking, monitoring, and following up on patients eGFR values and renal health | |
| · extra time and workload for provider to address patient fears and concerns regarding meaning of eGFR value and CKD stage/status (phone calls, creating patient letters) | |
Clinicians also discussed being appreciative of the information, and wished they’d had the information earlier because there were patients in whom opportunities for clinical intervention were previously missed. They said eGFR, and the subsequent staging of CKD, gives them a better picture of renal health than they could get with serum creatinine alone. Clinicians mentioned that their awareness of CKD was greater with eGFR being automatically reported. For example, before automated reporting some patients with a normal serum creatinine were missed as having CKD. They said like the reporting allowed them to identify those patients and take appropriate action like referral to nephrology. While it is recommended at KPNW that patients be referred to a nephrologist when their eGFR falls below 30, there are no barriers to referral at any level of kidney function. Clinicians reported improved patient management because it allowed them to assess and act on patient’s renal health at earlier stages than with serum creatinine alone. Additionally they noted that the appropriateness of medication and medication dosing was improved. They also discussed organizational financial improvements related to more accurate diagnosis, specifically Medicare.
Several concerns of eGFR reporting were also noted, including patient confusion and increased clinician workload. At KPNW it is common for patients to be sent a record of their laboratory values, including automated eGFR reporting. Especially in the initial phase of automated reporting, some patients ‘suddenly’ had kidney dysfunction, causing patient confusion and some anxiety over their health. For example, patients were confused about the new information including seeing two values of eGFR (one for black, and one for non-black), and were also concerned about their risk of renal dialysis. Addressing these patient concerns translated into added workload for clinicians by necessitating phone calls and explanatory letters to be sent. The dual reporting of two values by race also caused a ‘thinking’ burden for clinicians since they were not able to simply examine the eGFR value without also determining the patient’s race. Perhaps the most important burden perceived to clinician workload was that of adding another disease to manage, because eGFR reporting revealed a new and potentially quite large group of patients to manage. Allied Health providers reported being less likely to incorporate a diagnosis of CKD into the patient’s health record, and some clinicians reported creating systems to monitor and track eGFR values for their patients.
Table
Comparison of Work Practices Related to CKD Management since Automatic eGFR Reporting (n = 19)
| | | | ||
| · increased counseling / education discussions with patients about GFR value, kidney health, and CKD management | 6 (yes) | 4 (yes) | 10 | |
| 7 (no) | 2 (no) | 9 | ||
| · created specialized letters and phone talking points for explaining eGFR results and follow up activities to patients | 9 (yes) | 4 (yes) | 13 | |
| 4 (no) | 2 (no) | 6 | ||
| | | | ||
| · subtle increase (approx. 1 to 2 month) | 8 | 6 | 14 | |
| · no perceived increase in referrals | 4 | 0 | 4 | |
| · believe referrals have decreased | 1 | 0 | 1 | |
| | | | ||
| · eGFR value low 40’s to 40 | 1 | 4 | 5 | |
| · eGFR value 35 or less | 4 | 0 | 4 | |
| · eGFR value 15 to 30 | 4 | 0 | 4 | |
| · Base it on creatinine not eGFR | 0 | 1 | 1 | |
| · did not offer typical cut-off value (based on trends over time) | 4 | 1 | 5 | |
| | | | ||
| · refer more to class now | 1 | 1 | 2 | |
| · refer infrequently to occasionally | 4 | 3 | 7 | |
| · never refers to class | 2 | 0 | 2 | |
| · no awareness of class/did not mention | 6 | 2 | 8 |
Most clinicians (74%) said that they had increased their overall referrals to Nephrology, but only very slightly. Four of the 13 physicians did not believe eGFR automated reporting had any impact on their referrals, as they still tended to manage and treat their patients up to a later CKD stage of 4 prior to referring. However, all the allied health practitioners reported a perceived increase in referrals, and allied health practitioners were more likely to refer at higher eGFRs (i.e. for less sick patients) than physicians. Physicians divided evenly between referring at late CKD stage 3b and 4, while most allied health reported referring to nephrology at earlier CKD stage 3a. Slightly less than half the clinicians (47%) reported ever referring to the HMO’s ‘kidney class’, a dietician-led class aimed at helping patients take a greater role in their kidney health; most clinicians said their referral pattern to this class did not change with eGFR reporting.
The clinicians we interviewed had several suggestions for improving the utilization of automated eGFR reporting, and for improving their overall CKD management. Ongoing clinician education, using a case-study approach, was noted as something they desired and suggested these trainings could be made available both in-person and on-line. They reported being especially interested in 1) why it is better to use eGFR (versus serum creatinine), 2) how eGFR should be used clinically at different CKD stages, and 3) best ways to communicate to patients about their eGFR at different CKD stages (Table
Suggestions for Future Needs to Improve Utilization of eGFR Value and Overall CKD Management (n = 19)
| · yearly trainings both in-person and on-line | |
| · trainings to focus on: why use eGFR; how to best use it at different states/values; how to best communicate and educate patients at different values/stages | |
| · provide case-study approach highlighting different patient scenarios | |
| · provide both opportunity and responses to provider questions/concerns | |
| · Provide yearly to twice yearly feedback on the provider’s actions related to such things as: | |
| → referral patterns to Nephrology appropriately – is it too much or coming too late | |
| → ordering patterns for follow up labs and tests - are the appropriate labs and tests being ordered at the appropriate times | |
| → identification of whether there is anything else the provider could be doing for the patient both prior to and after referral to Nephrology | |
| · update and re-send out laminated card summarizing current CKD guidelines and “best practice” referral patterns based on eGFR value | |
| · create several different letter templates and phone scripts (based on eGFR value and CKD staging) for use by providers and medical assistants in their discussions and communication with members | |
| · yearly reminders of where to access CKD guidelines on-line, and any changes in the guidelines | |
| · yearly reminders of the Kidney class option, including where, when, and how often it occurs and the appropriate circumstances to refer patients to class | |
| · consistent, automatic process for eGFR value and follow ups to be reported in commonly used areas of the EMR – such as patient problem list; results reporting; and trended results | |
| · improve ability of computer to correctly impute race so providers and patients see only one eGFR value rather than both on lab results, outreach prompts, or patient letters | |
| · continue to improve and refine smart set tools in the internal referral process of EMR to facilitate proper lab orders and follow up by providers | |
| · create standard, uniform hand-outs for providers to use with patients to help explain kidney functioning, meaning of eGFR values, and CKD staging | |
| · create visual exam room posters of the kidneys and how they function to assist with provider communication and education to patients | |
| · improve patient information and education about CKD and kidney functioning on the organization’s external website | |
*
Clinicians were also interested in hearing feedback, on an on-going basis, from nephrology on their actions related to CKD care. They particularly mentioned desiring feedback on timing of nephrology referrals, ordering of follow-up laboratory tests and the timing if these tests, and clinical care they should be providing both before and after nephrology referral.
Other specific types of needs identified were related to clinician tools and reminders. In the past, the HMO’s department of nephrology supplied laminated 4″ × 6″ cards that summarized CKD guidelines and best practices. Several clinicians, particularly allied health practitioners, mentioned that they had found these helpful and would like them updated and made available. Clinicians also desired help with patient communication templates for both letters and telephone scripts that could be used by them and their medical assistants. They also mentioned it would be helpful to have reminders of where to access CKD guidelines and reminders of options for patient education such as the aforementioned kidney class.
Clinicians had several suggestions for the integration of the eGFR reporting into the EMR. Some of these suggestions had to do with reminders to obtain follow-up laboratory measures, perhaps incorporated into patients’ diagnosis list, in the laboratory values reports, and in the section of the EMR that reports trended laboratory values. They also discussed the need to address the confusion over the eGFR report containing two values that depend on race. Clinicians also expressed a desire to see improvements in the ability of the EMR to facilitate appropriate laboratory orders and follow-up, for example through ‘smart sets’ that automatically allow a pended order for future laboratory kidney-related tests.
The clinicians we interviewed were also keen to see more patient related education tools, including handouts that explain kidney function, the meaning of eGFR and CKD staging. They said exam room posters of kidney function could facilitate communication with patients, and that the HMO’s external website could be used to improve communication about kidney health.
We found that clinicians were aware of eGFR reporting and generally held favorable views toward it, but also noted some barriers to its use. Perhaps the most interesting theme that emerged from our interviews was that eGFRs were not used to replace serum creatinines, but were used as an added source of information. Clinicians used eGFR as a tool to help: 1) identify CKD; 2) educate patients about their kidney function and; 3) make treatment decisions. The clinicians we interviewed suggested that the added gradation provided by eGFR allowed them to identify CKD at earlier stages than serum creatinine alone, but for most of the clinicians we interviewed the eGFR did not replace serum creatinine as an indication of later staged kidney disease.
It appears from clinician responses that serum creatinine is used as a means of validating eGFR measures. While this may seem redundant, it may be entirely appropriate. Though serum creatinine overestimates renal function when it is poor, eGFR underestimates renal function when it is normal [
Reporting of eGFR has seemingly created a greater awareness of kidney dysfunction among the clinicians we interviewed. This is a significant finding because that enhanced awareness highlights shortcomings in clinician education; in fact, suggestions made by the clinicians we interviewed to improve utilization of eGFR value revolved primarily around clinician education. Interaction between nephrologists and primary care physicians would appear to play an important role in how eGFRs are utilized. KPNW has made efforts to educate primary care clinicians (CME conferences, written literature, guidelines embedded in the EMR), and the message from our study illustrate that ongoing educational efforts are important. It may also suggest that, because busy primary care clinicians can’t always avail themselves of these opportunities, it is incumbent on the system to advertise the educational opportunities widely, on an on-going basis, and offer several venues to accommodate varied learning and practice styles. The need for clinician education is likely to be greater in other medical systems that have not undertaken similar efforts.
Our study was qualitative, meaning it lacks the empiric information necessary to discern whether the responses represented the feelings of clinicians across the Kaiser Permanente system, or whether they can be extrapolated to other clinicians and medical systems. For example, our findings are specific to a health system with an extant, fully functioning EMR. Such a system may allow clinicians more immediate access to ancillary information (e.g. guidelines) about eGFR interpretation, perhaps easing the transition. The opinions expressed may have been different if the interviews were conducted by a different interviewer or if solicited by another means (i.e. a survey). Additionally, our modest number of interviews may yield less stable frequency estimates than if we had access to a larger sample. But strengths of our approach include the use of a pre-specified interview guide, use of trained interviewers, and interviewing to “saturation”.
The manner in which clinicians use eGFRs appears to be more complex than previously understood, and our study illustrates some of the efforts that might be usefully undertaken (e.g. specific clinician education) when encouraging further promulgation of eGFR reporting and usage.
The authors declare they have no competing interests.
DS, JS, MT, SV, JW, EJ, AF, SS contributed to the methodology, study design, analysis and drafting of the manuscript. AP and XY performed the analysis of the material and drafting of the manuscript. JS also conducted the interviews. All authors read and approved the final maunscript.
The pre-publication history for this paper can be accessed here: